Classifications

• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• RPTKs receptor protein tyrosine kinases
• EGF epidermal growth factor
• EGFR epidermal growth factor receptor
• cyclin dependent kinase 2 (cdk2), a kinase important in regulating cellular proliferation
• cdk2 cyclin dependent kinase 2
• NEGFR vascular endothelial growth factor receptor
• Inhibition of VEGFR activity reduces or eliminates the vascularization of tumors directed by NEGFR.
• An antagonistic monoclonal antibody, herceptin, against the erbB2 receptor tyrosine kinase is being used in breast cancer therapies to treat breast cancers where ErbB2 is overexpressed.
• the fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X
• the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14.
• the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention.
• preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone).
• preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).
• the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
• HCE3W04 379 615501 AC022366 1466 1-565 1503-1718 1838-1933 2011-2097 2265-2335 2588-2693 2905-2975 3090-3726 3809-3889 4080-4591 4847-5070 5355-5819
• the fourth column provides a BAC identifier "BAC ID NO: A” for the BAC clone referenced in the corresponding row of the table.
• the fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table.
• the sixth column provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
• polypeptides of the invention can be prepared in any suitable manner.
• Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
• polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1), or any combination thereof.
• the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table IB, column 5).
• polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous.
• polynucleotides of the invention -comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table IB are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
• Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the mvention.
• polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same Clone ID NO:Z (see Table IB, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention.
• Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the mvention.
• Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
• polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3.
• the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone).
• HUTSF11 241 966029 1 - 416 15 - 430 AI384010, AI288640, Z20435, and A74523.
• polypeptide and Polypeptide Variants [98] The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, nucleotide sequences encoding the polypeptide of SEQ ID NO:Y, the nucleotide sequence of SEQ ID NO:X encoding the polypeptide sequence as defined in column 7 of Table 1A, nucleotide sequences encoding the polypeptide as defined in column 7 of Table 1 A, the nucleotide sequence as defined in columns 8 and 9 of Table 2, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, the nucleotide sequence as defined in column 6 of Table IB, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in column 6 of Table IB, the cDNA sequence contained in Clone ID NO:Z, and/or nucleotide sequences
• one aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence described in SEQ ID NO:X or contained in the cDNA sequence of Clone ID NO:Z; (b) a nucleotide sequence in SEQ ID NO:X or the cDNA in Clone ID NO:Z which encodes the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (c) a nucleotide sequence in SEQ ID NO:X or the cDNA in Clone ID NO:Z which encodes a mature polypeptide; (d) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of Clone ID NO:Z, which encodes a biologically active fragment of a polypeptide; (e) a nucleotide sequence
• the present mvention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%> or 100%), identical to, for example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), or (j) above, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the cDNA contained in Clone ID NO:Z or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X,
• polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides and nucleic acids.
• the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under lower stringency conditions, to a polynucleotide in (a), (b), (c), (d), (e), (f), (g), (h), or (i), above, as are polypeptides encoded by these polynucleotides.
• the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment.
• a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity.
• the deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end.
• the 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%.
• a 90 base subject sequence is compared with a 100 base query sequence.
• deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query.
• percent identity calculated by FASTDB is not manually corrected.
• bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

Landscapes

• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (235)

Publications (1)

Family

ID=27587097

Family Applications (38)

Family Applications Before (20)

Family Applications After (17)

Country Status (1)

Families Citing this family (4)

• 2001
  • 2001-01-17 EP EP01916068A patent/EP1255817A1/de not_active Withdrawn
  • 2001-01-17 EP EP01924086A patent/EP1259531A2/de not_active Withdrawn
  • 2001-01-17 EP EP01924081A patent/EP1254153A2/de not_active Withdrawn
  • 2001-01-17 EP EP01918156A patent/EP1254151A1/de not_active Withdrawn
  • 2001-01-17 EP EP01912650A patent/EP1255777A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910330A patent/EP1255768A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912654A patent/EP1254172A1/de not_active Withdrawn
  • 2001-01-17 EP EP01912662A patent/EP1255767A2/de not_active Withdrawn
  • 2001-01-17 EP EP01910331A patent/EP1259540A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910329A patent/EP1255766A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912664A patent/EP1255778A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912655A patent/EP1261703A1/de not_active Withdrawn
  • 2001-01-17 EP EP01928288A patent/EP1254147A2/de not_active Withdrawn
  • 2001-01-17 EP EP01924085A patent/EP1261745A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912653A patent/EP1252185A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910335A patent/EP1254218A2/de not_active Withdrawn
  • 2001-01-17 EP EP01910328A patent/EP1261634A1/de not_active Withdrawn
  • 2001-01-17 EP EP01908611A patent/EP1261633A2/de not_active Withdrawn
  • 2001-01-17 EP EP01920103A patent/EP1261637A1/de not_active Withdrawn
  • 2001-01-17 EP EP01908617A patent/EP1252290A1/de not_active Withdrawn
  • 2001-01-17 EP EP01912649A patent/EP1261380A1/de not_active Withdrawn
  • 2001-01-17 EP EP01912658A patent/EP1254248A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912656A patent/EP1252176A2/de not_active Withdrawn
  • 2001-01-17 EP EP01914330A patent/EP1252297A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910336A patent/EP1252302A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912651A patent/EP1252303A2/de not_active Withdrawn
  • 2001-01-17 EP EP01914331A patent/EP1254173A1/de not_active Withdrawn
  • 2001-01-17 EP EP01912657A patent/EP1261618A2/de not_active Withdrawn
  • 2001-01-17 EP EP01922230A patent/EP1259526A2/de not_active Withdrawn
  • 2001-01-17 EP EP01920102A patent/EP1254152A2/de not_active Withdrawn
  • 2001-01-17 EP EP01910332A patent/EP1255864A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910337A patent/EP1255776A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910334A patent/EP1259642A1/de not_active Withdrawn
  • 2001-01-17 EP EP01926335A patent/EP1263944A2/de not_active Withdrawn
  • 2001-01-17 EP EP01924084A patent/EP1265910A2/de not_active Withdrawn
  • 2001-01-17 EP EP01912652A patent/EP1254171A1/de not_active Withdrawn
  • 2001-01-17 EP EP01910326A patent/EP1252289A2/de not_active Withdrawn
  • 2001-01-17 EP EP01910325A patent/EP1254219A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events